Since 2012, the Cancer Research Institute has partnered with MedImmune, a member of the AstraZeneca Group, to advance clinical trials to test novel combinations of cancer immunotherapies. CRI is conducting trials using investigational drugs that MedImmune has provided through this partnership from its product pipeline.

AstraZeneca’s support of educational programming includes funding the 2017 Immunotherapy Patient Summit series and multi-year funding for Cancer Immunotherapy Month. Additionally, AstraZeneca provided multi-year support for the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and Annual Awards Dinner. AstraZeneca has also supported the CRI Irvington Postdoctoral Fellowship Program.

*Immunotherapy results may vary from patient to patient.

Top